Guo Jinlei, Yan Yong, Zhang Jiafeng, Ji Jimei, Ge Zhijian, Ge Rui, Zhang Xiaofei, Wang Henghui, Chen Zhongwen, Luo Jianyong
Jiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Municipal Center for Disease Control and Prevention, Jiaxing 314001, PR China.
Institute of AIDS Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China.
Oncotarget. 2017 Mar 14;8(11):18271-18279. doi: 10.18632/oncotarget.15382.
The aim of this study was to characterize HIV-1 genotypes and antiretroviral resistance mutations among treatment-naive HIV-infected individuals in Jiaxing, China. The HIV-1 partial polymerase (pol) genes in 93 of the 99 plasma samples were successfully amplified and analyzed. Phylogenetic analysis revealed the existence of five HIV-1 genotypes, of which the most prevalent genotype was CRF01_AE (38.7%), followed by CRF07_BC (34.4%), CRF08_BC (16.1%), subtype B/B' (5.4%), and CRF55_01B (2.1%). Besides, three types of unique recombination forms (URFs) were also observed, including C/F2/A1, CRF01_AE/B, and CRF08_BC/CRF07_BC. Among 93 amplicons, 46.2% had drug resistance-associated mutations, including 23.7% for protease inhibitors (PIs) mutations, 1.1% for nucleoside reverse transcriptase inhibitors (NRTIs) mutations, and 20.4% for non-nucleoside reverse transcriptase inhibitors (NNRTIs) mutations. Six (6.5%) out of 93 treatment-naive subjects were identified to be resistant to one or more NNRTIs, while resistance to NRTIs or PIs was not observed. Our study showed the genetic diversity of HIV-1 strains circulating in Jiaxing and a relative high proportion of antiretroviral resistance mutations among treatment-naive patients, indicating a serious challenge for HIV prevention and treatment program.
本研究的目的是对中国嘉兴市初治HIV感染个体中的HIV-1基因型和抗逆转录病毒耐药性突变进行特征分析。99份血浆样本中的93份样本的HIV-1部分聚合酶(pol)基因被成功扩增并分析。系统发育分析显示存在五种HIV-1基因型,其中最常见的基因型是CRF01_AE(38.7%),其次是CRF07_BC(34.4%)、CRF08_BC(16.1%)、B/B'亚型(5.4%)和CRF55_01B(2.1%)。此外,还观察到三种独特的重组形式(URF),包括C/F2/A1、CRF01_AE/B和CRF08_BC/CRF07_BC。在93个扩增子中,46.2%存在与耐药相关的突变,其中蛋白酶抑制剂(PI)突变占23.7%,核苷类逆转录酶抑制剂(NRTI)突变占1.1%,非核苷类逆转录酶抑制剂(NNRTI)突变占20.4%。93名初治受试者中有6名(6.5%)被确定对一种或多种NNRTI耐药,而未观察到对NRTI或PI的耐药情况。我们的研究显示了嘉兴市流行的HIV-1毒株的遗传多样性以及初治患者中抗逆转录病毒耐药性突变的相对高比例,这表明HIV预防和治疗计划面临严峻挑战。